Loading company…
Newdel Biotech discovers and develops small molecule drugs, with a focus on oncology.
Newdel Biotech researches and develops small molecule drugs, including antitumor candidates, immune checkpoint inhibitors, and treatments for infectious and metabolic diseases. Its DEL+X platform uses DNA Encoded Library technology and includes a compound library of more than 100 billion real molecules. Based in Shenzhen, China, the company was established in 2021.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in